Piper Jaffray maintains an 'Overweight' rating on Genzyme Corporation (Nasdaq: GENZ), price target lowered from $74 to $71.

Piper analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE